Loading stock data…
DBV Technologies S.A. (DBVT)
$13.27-0.20 (-1.48%)
Market ClosedLast close Sep 8
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DBV Technologies S.A. in the Healthcare sector is trading at $13.27 with a market capitalization of $804M. Wall Street consensus targets $41.49 (6 analysts), implying a +212.7% move over the next 12 months. The stock is currently 49% below its 52-week high of $26.18, remaining 26.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +212.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.60M↓ | -$47.90M↓ | -$45.05M↓ | -$34.28M↑ | -$41.20M |
| Net Income | -$50.40M↓ | -$47.60M↓ | -$44.83M↓ | -$33.16M↑ | -$41.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$803.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-109.65%
Volume
Today's trading volume
181,286
Recent News
European Equities Traded in the US as American Depositary Receipts Marginally Higher in Friday Trading
European equities traded in the US as American depositary receipts were marginally higher late Frida
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher lat
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
European equities traded in the US as American depositary receipts were marginally higher late Frida
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading
European equities traded in the US as American depositary receipts were marginally higher late Tuesd